| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 5-FU is a chemotherapy medication used to treat various types of cancer, including colorectal, breast, stomach, and pancreatic cancer. It belongs to a class of drugs known as antimetabolites, which work by interfering with the growth and replication of cancer cells. Mechanisms: - functionally irreversibly inhibits Thymidylate Synthase (TS), thereby depleting the deoxythymidine monophosphate (dTMP) pool required for DNA synthesis. The resulting “thymineless death” prevents DNA replication and repair, particularly affecting rapidly proliferating tumor cells. 5-FU is a cornerstone in chemotherapy with a dual mechanism of action—primarily inhibiting thymidylate synthase (leading to disruption of DNA synthesis) and interfering with RNA processing by misincorporation. Its metabolism via activation (OPRT) and degradation (DPD) plays a crucial role in both its effectiveness and toxicity. Clinically, 5-FU is extensively used in treating a variety of cancers, most notably colorectal cancer, and remains a mainstay in multi-agent chemotherapeutic regimens due to its proven efficacy across diverse cancer types. 5-FU is one of the most common chemotherapeutic agents worldwide, particularly noted in gastrointestinal (GI) cancers.
Time-Scale Flag (TSF): P / R / G
|
| Source: |
| Type: |
| LDHA is a key enzyme that catalyzes the conversion of pyruvate into lactate while regenerating NAD+, essential for glycolysis. Elevated levels of LDHA have been associated with increased tumor growth and survival. By promoting lactate production, cancer cells can create an acidic microenvironment that may facilitate invasion and metastasis. Is often upregulated in various types of cancer, including breast, lung, colorectal, and prostate cancers. This upregulation is associated with the metabolic shift that cancer cells undergo to support rapid growth and proliferation. Measuring the lactate dehydrogenase (LDH) is a useful method for detection of necrosis. |
| - | in-vitro, | CRC, | NA |
| 2295- | Ba, | 5-FU, | Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway |
| - | in-vitro, | GC, | AGS |
| 939- | Catechins, | 5-FU, | Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil |
| - | vitro+vivo, | GC, | SNU620 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:191 Target#:175 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid